Advances in understanding migraine pathophysiology: a bench to bedside review of research insights and therapeutics
The individual and global burden of migraine is of such significance that there are accelerated efforts to develop new therapies. New migraine therapeutics are needed to address the current deficiencies that exist in the efficacy and adherence rate of approved anti-migraine medications. The recent d...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2024-02-01
|
| Series: | Frontiers in Molecular Neuroscience |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fnmol.2024.1355281/full |
| _version_ | 1797293117029744640 |
|---|---|
| author | Kofi Frimpong-Manson Yuma T. Ortiz Lance R. McMahon Jenny L. Wilkerson |
| author_facet | Kofi Frimpong-Manson Yuma T. Ortiz Lance R. McMahon Jenny L. Wilkerson |
| author_sort | Kofi Frimpong-Manson |
| collection | DOAJ |
| description | The individual and global burden of migraine is of such significance that there are accelerated efforts to develop new therapies. New migraine therapeutics are needed to address the current deficiencies that exist in the efficacy and adherence rate of approved anti-migraine medications. The recent discovery of the calcitonin gene related peptide as an add-on to the role of serotonin has markedly increased the range of new treatment options for acute and chronic migraine. Despite this, tackling the complexity of migraine disorders requires a complete understanding of its pathophysiology. Preclinical animal models can shed light on disease-related pathophysiology, including migraine. Indeed, the use of animal models has been instrumental in developing many therapeutics. However, an animal model is limited by the predictive and face validity of that model, and this extends to preclinical migraine models. In this review, a summary of the current understanding of the pathophysiology of migraine is given from both a preclinical and clinical perspective, and an emphasis is placed on the animal models of migraine. We will discuss the strengths and pitfalls of common preclinical migraine models as well as experimental research areas to explore further. |
| first_indexed | 2024-03-07T20:08:15Z |
| format | Article |
| id | doaj.art-b546ac27c15946b2960427b79b569952 |
| institution | Directory Open Access Journal |
| issn | 1662-5099 |
| language | English |
| last_indexed | 2024-03-07T20:08:15Z |
| publishDate | 2024-02-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Molecular Neuroscience |
| spelling | doaj.art-b546ac27c15946b2960427b79b5699522024-02-28T04:18:33ZengFrontiers Media S.A.Frontiers in Molecular Neuroscience1662-50992024-02-011710.3389/fnmol.2024.13552811355281Advances in understanding migraine pathophysiology: a bench to bedside review of research insights and therapeuticsKofi Frimpong-MansonYuma T. OrtizLance R. McMahonJenny L. WilkersonThe individual and global burden of migraine is of such significance that there are accelerated efforts to develop new therapies. New migraine therapeutics are needed to address the current deficiencies that exist in the efficacy and adherence rate of approved anti-migraine medications. The recent discovery of the calcitonin gene related peptide as an add-on to the role of serotonin has markedly increased the range of new treatment options for acute and chronic migraine. Despite this, tackling the complexity of migraine disorders requires a complete understanding of its pathophysiology. Preclinical animal models can shed light on disease-related pathophysiology, including migraine. Indeed, the use of animal models has been instrumental in developing many therapeutics. However, an animal model is limited by the predictive and face validity of that model, and this extends to preclinical migraine models. In this review, a summary of the current understanding of the pathophysiology of migraine is given from both a preclinical and clinical perspective, and an emphasis is placed on the animal models of migraine. We will discuss the strengths and pitfalls of common preclinical migraine models as well as experimental research areas to explore further.https://www.frontiersin.org/articles/10.3389/fnmol.2024.1355281/fullserotonincalcitonin gene related peptide (CGRP)cannabinoidrodentcortical spreading depressionpurinergic receptor |
| spellingShingle | Kofi Frimpong-Manson Yuma T. Ortiz Lance R. McMahon Jenny L. Wilkerson Advances in understanding migraine pathophysiology: a bench to bedside review of research insights and therapeutics Frontiers in Molecular Neuroscience serotonin calcitonin gene related peptide (CGRP) cannabinoid rodent cortical spreading depression purinergic receptor |
| title | Advances in understanding migraine pathophysiology: a bench to bedside review of research insights and therapeutics |
| title_full | Advances in understanding migraine pathophysiology: a bench to bedside review of research insights and therapeutics |
| title_fullStr | Advances in understanding migraine pathophysiology: a bench to bedside review of research insights and therapeutics |
| title_full_unstemmed | Advances in understanding migraine pathophysiology: a bench to bedside review of research insights and therapeutics |
| title_short | Advances in understanding migraine pathophysiology: a bench to bedside review of research insights and therapeutics |
| title_sort | advances in understanding migraine pathophysiology a bench to bedside review of research insights and therapeutics |
| topic | serotonin calcitonin gene related peptide (CGRP) cannabinoid rodent cortical spreading depression purinergic receptor |
| url | https://www.frontiersin.org/articles/10.3389/fnmol.2024.1355281/full |
| work_keys_str_mv | AT kofifrimpongmanson advancesinunderstandingmigrainepathophysiologyabenchtobedsidereviewofresearchinsightsandtherapeutics AT yumatortiz advancesinunderstandingmigrainepathophysiologyabenchtobedsidereviewofresearchinsightsandtherapeutics AT lancermcmahon advancesinunderstandingmigrainepathophysiologyabenchtobedsidereviewofresearchinsightsandtherapeutics AT jennylwilkerson advancesinunderstandingmigrainepathophysiologyabenchtobedsidereviewofresearchinsightsandtherapeutics |